Download PDF
Zeitschrift für Phytotherapie 2015; 36(01): 4-9
DOI: 10.1055/s-0034-1395839
Forschung
© Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Vitex agnus-castus: Evidenzbasierte Therapie bei zyklusabhängigen Beschwerden

André-Michael Beer
Further Information

Publication History

Publication Date:
16 March 2015 (online)

    Permissions and Reprints

Zusammenfassung

Vitex agnus-castus L. ist eine bewährte Arzneipflanze zur Behandlung zyklusabhängiger Beschwerden. Umfangreiche pharmakologische und klinische Daten untermauern den Stellenwert des Mönchspfeffers als evidenzbasierte Therapieoption. Extrakte aus den getrockneten Früchten zeigen dopaminerge Wirkungen und können damit eine Hyperprolaktinämie günstig beeinflussen, welche Zyklusbeschwerden in vielen Fällen zugrunde liegt. Mastodynien, prämenstruelle Beschwerden sowie Regeltempoanomalien können effektiv behandelt werden. Auch bei Corpus-luteum-Insuffizienz-bedingter Infertilität und Dysmenorrhö ist der Einsatz von Vitex agnus-castus sinnvoll.

Summary

Vitex agnus-castus: evidence-based treatment of menstrual cycle complaints

Vitex agnus-castus L. is a proven medicinal herb for treating menstrual cycle-related complaints. Extensive pharmacological and clinical data support the significance of Vitex agnus-castus as evidence-based treatment option. Extracts from the dried fruits show dopaminergic effects and can therefore have a positive effect on hyperprolactinemia, in many cases the cause of menstrual cycle complaints. Breast tenderness, premenstrual symptoms and cycle irregularities can be effectively treated. In addition, the use of Vitex agnus-castus is reasonable for the treatment of corpus luteum insufficiency-related infertility and dysmenorrhea.

Schlüsselwörter

Vitex agnus-castus L - Mönchspfeffer - Mastodynie - prämenstruelles Syndrom - Regeltempoanomalien - Hyperprolaktin­ämie

Keywords

Vitex agnus-castus L - chasteberry - mastodynia - premenstrual syndrome - cycle irregularities - hyperprolactinemia
 

  • Literatur

  • 1 Kommission E. Monographie „Agni casti ­fructus (Keuschlammfrüchte)“. BAnz Nr. 226 vom 2.12.1992
    PubMedGoogle Scholar
  • 2 Beer AM, Schilcher H, Loew D. Phytopharmaka als Alternative zu Synthetika. MMW-Fortschr Med Originalien 2013; 155: 97-99
    PubMedGoogle Scholar
  • 3 European Medicines Agency. Community ­herbal monograph on Vitex agnus-castus L., fructus. 25 November 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_Community_herbal_monograph/2011/08/WC500110099.pdf
    PubMed
  • 4 Wuttke W, Seidlová-Wuttke D, Jarry H, Artymuk N. Der Stellenwert des Mönchspfeffers (Vitex agnus-castus) in der gynäkologischen Endokrinologie. Z Phytother 2010; 31: 294-298
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Jarry H, Leonhardt S, Gorkow C, Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol 1994; 102: 448-454
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Wuttke W, Jarry H, Christoffel V et al. Chaste tree (Vitex agnus-castus) − pharmacology and clinical indications. Phytomedicine 2003; 10: 348-357
    Google Scholar
  • 7 Röhrl J, Mähler N, Künstle G, Haunschild J. Receptor targeting activities for Vitex agnus- castus dry extract (BNO 1095) as active component of Agnucaston®. Poster, 17th Inter­national Congress Phytopharm, Vienna 2013
    PubMedGoogle Scholar
  • 8 Kilicdag EB, Tarim E, Bagis T et al. Fructus agni casti and bromocriptine for treatment of hyper­prolactinemia and mastalgia. Int J ­Gynaecol Obstet 2004; 85: 292-293
    PubMedGoogle Scholar
  • 9 Webster DE, He Y, Chen SN et al. Opioidergic mechanisms underlying the actions of Vitex agnus-castus L. Biochem Pharmacol 2011; 81: 170-177
    CrossrefPubMedGoogle Scholar
  • 10 Röhrl J, Künstle G, Haunschild J. The Vitex agnus-­castus dry extract BNO 1095 contained in Agnucaston® is effective to prevent uterus contractions in vitro. Poster, 16th World ­Congress of the International Society of ­Gynecological Endocrinology (ISGE), Firenze 2014
    PubMedGoogle Scholar
  • 11 van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus extracts for female repro­duc­tive disorders: a systematic review of ­clinical trials. Planta Med 2013; 79: 562-575
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 He Z, Chen R, Zhou Y et al. Treatment for premenstrual syndrome with Vitex agnus castus: A prospective, randomized, multi-­center ­placebo controlled study in China. Maturitas 2009; 63: 99-103
    CrossrefPubMedGoogle Scholar
  • 13 Ma L, Lin S, Chen R, Wang X. Treatment of ­moderate to severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Gynecol Endocrinol 2010; 26: 612-616
    CrossrefPubMedGoogle Scholar
  • 14 Prilepskaya VN, Ledina AV, Tagiyeva AV, Revazova FS. Vitex agnus castus: Successful ­treatment of moderate to severe premenstrual syndrome. Maturitas 2006; 55 (Suppl. 1): S55-S63
    CrossrefPubMedGoogle Scholar
  • 15 Berger D, Schaffner W, Schrader E et al. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet 2000; 264: 150-153
    CrossrefPubMedGoogle Scholar
  • 16 Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 2001; 322: 134-137
    CrossrefPubMedGoogle Scholar
  • 17 Schellenberg R, Zimmermann C, Drewe J et al. Dose-dependent efficacy of the Vitex agnus castus extract Ze 440 in patients suffering from premenstrual syndrome. Phytomedicine 2012; 19: 1325-1331
    CrossrefPubMedGoogle Scholar
  • 18 Loch EG, Selle H, Boblitz N. Treatment of ­premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus . J Womens Health Gend Based Med 2000; 9: 315-320
    CrossrefPubMedGoogle Scholar
  • 19 Onaran Y, Kurtay G, Binici S. Premenstrual Mood. A comparison of the activity of Vitex agnus castus extract and oral contraceptives on mood in premenstrual syndrome. Kadin Dogum Dergisi 2003; 2: 73-77
    PubMedGoogle Scholar
  • 20 Atmaca M, Kumru S, Tezcan E. Fluoxetine ­versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol 2003; 18: 191-195
    CrossrefPubMedGoogle Scholar
  • 21 Lauritzen C, Reuter HD, Repges R et al. Treatment of premenstrual tension syndrome with Vitex agnus castus. Controlled, double-­blind study versus pyridoxine. Phytomedicine 1997; 4: 183-189
    CrossrefPubMedGoogle Scholar
  • 22 Aydin I, Baltaci D, Türkyilmaz S, Öncü M. ­Comparison of Vitex agnus castus with melo­xicam and placebo in treatment of patients with cyclical mastalgia. Düzce Tip Dergisi 2012; 14: 1-5
    PubMedGoogle Scholar
  • 23 Dinc T, Coskun F. Comparison of fructus agni casti and flurbiprofen in the treatment of ­cyclic mastalgia in premenopausal women. Ulusal Cer Derg 2014; 30: 34-38
    PubMedGoogle Scholar
  • 24 Milewicz A, Gejdel E, Sworen H et al. Vitex ­agnus castus-Extrakt zur Behandlung von ­Regeltempoanomalien infolge latenter Hyperprolaktinämie. Ergebnisse einer randomisierten Plazebo-kontrollierten Doppelblindstudie. Arzneimittelforschung 1993; 43: 752-756
    PubMedGoogle Scholar
  • 25 Eltbogen R, Litschgi M, Gasser UE et al. Vitex agnus-castus extract (Ze 440) improves symptoms in women with menstrual cycle irregularities. Planta Med 2014; 80 SL19
    PubMedGoogle Scholar
  • 26 Aksoy AN, Gözükara I, Kabil Kucur S. Evaluation of the efficacy of fructus agni casti in women with severe primary dysmenorrhea: a prospective comparative Doppler study. J Obstet Gynaecol Res 2014; 40: 779-784
    CrossrefPubMedGoogle Scholar
  • 27 Berger D. Vitex agnus-castus: Unbedenklichkeit und Wirksamkeit beim prämenstruellen Syndrom. Wirkprinzipien und Wirkmechanismen eines neu entwickelten Extraktes [Dissertation]. Basel: Universität; 1998
    Google Scholar
  • 28 Liu J, Burdette JE, Xu H et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem 2001; 49: 2472-2479
    CrossrefPubMedGoogle Scholar
  • 29 Jarry H, Leonhardt S, Gorkow C, Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol 1994; 102: 448-454
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Sliutz G, Speiser P, Schultz AM et al. Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. Horm Metab Res 1993; 25: 253-255
    Google Scholar
  • 31 Christoffel V, Spengler B, Jarry H et al. Selective estrogenic activity of Vitex agnus-castus . Revista de Fitoterapia 2002; 2 (Suppl. 1, SL10): 63-
    PubMedGoogle Scholar
  • 32 Jarry H, Spengler B, Porzel A et al. Evidence for estrogen receptor β-selective activity of Vitex agnus-castus and isolated flavones. Planta Med 2003; 69: 945-947
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Jarry H, Spengler B, Wuttke W, Christoffel V. In vitro assays for bioactivity-guided isolation of endocrine active compounds in Vitex agnus-castus . Maturitas 2006; 55 (Suppl. 1): S26-S36
    CrossrefPubMedGoogle Scholar
  • 34 Ye Q, Zhang QY, Zheng CJ et al. Casticin, a flavonoid isolated from Vitex rotundifolia, inhibits prolactin release in vivo and in vitro. Acta Pharmacol Sin 2010; 31: 1564-1568
    CrossrefPubMedGoogle Scholar
  • 35 Ohyama K Akaike T, Hirobe C, Yamakawa T. Cytotoxicity and apoptotic inducibility of Vitex agnus-castus fruit extract in cultured human normal and cancer cells and effect on growth. Biol Pharm Bull 2003; 26: 10-18
    CrossrefPubMedGoogle Scholar
  • 36 Obi N, Chang-Claude J, Berger J et al. The use of herbal preparations to alleviate climacteric disorders and risk of postmenopausal breast cancer in a German case-control study. Cancer Epidemiol Biomarkers Prev 2009; 18: 2207-2213
    CrossrefPubMedGoogle Scholar
  • 37 Deutsche Pharmazeutische Gesellschaft e.V. Gute Substitutionspraxis [Leitlinie]. Stand: 24.2.2014 http://www.dphg.de/fileadmin/content/pdfs/dphg_leitlinie_gute_substitutionspraxis.pdf
    PubMed